MA28151A1 - Derives de pyrazolyle et d'imidazolyle bicycliques et leurs utilisations - Google Patents
Derives de pyrazolyle et d'imidazolyle bicycliques et leurs utilisationsInfo
- Publication number
- MA28151A1 MA28151A1 MA29005A MA29005A MA28151A1 MA 28151 A1 MA28151 A1 MA 28151A1 MA 29005 A MA29005 A MA 29005A MA 29005 A MA29005 A MA 29005A MA 28151 A1 MA28151 A1 MA 28151A1
- Authority
- MA
- Morocco
- Prior art keywords
- imidazolyl derivatives
- bicyclic pyrazolyl
- pyrazolyl
- bicyclic
- imidazolyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Psychology (AREA)
- Obesity (AREA)
- Child & Adolescent Psychology (AREA)
- Nutrition Science (AREA)
- Hospice & Palliative Care (AREA)
- Anesthesiology (AREA)
- Emergency Medicine (AREA)
- Gynecology & Obstetrics (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Abstract
Dérivés de pyrazolyle et d¿imidazolyle bicycliques et leurs utilisations Des composés de formule (I) sont décrits dans le présent mémoire. Les composés se sont révélés jouer le rôle de ligands des récepteurs de cannabinoïdes et sont donc utiles dans le traitement de maladies liées à la médiation des récepteurs de cannabinoïdes chez des animaux.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US51828003P | 2003-11-07 | 2003-11-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA28151A1 true MA28151A1 (fr) | 2006-09-01 |
Family
ID=34572986
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA29005A MA28151A1 (fr) | 2003-11-07 | 2006-05-05 | Derives de pyrazolyle et d'imidazolyle bicycliques et leurs utilisations |
Country Status (29)
Country | Link |
---|---|
US (2) | US7151097B2 (fr) |
EP (1) | EP1682554A1 (fr) |
JP (2) | JP4056549B2 (fr) |
KR (1) | KR20060086396A (fr) |
CN (1) | CN1886407A (fr) |
AP (1) | AP2006003601A0 (fr) |
AR (1) | AR046831A1 (fr) |
AU (1) | AU2004286909A1 (fr) |
BR (1) | BRPI0416299A (fr) |
CA (1) | CA2544752A1 (fr) |
CR (1) | CR8387A (fr) |
DO (1) | DOP2004001024A (fr) |
EA (1) | EA009742B1 (fr) |
EC (1) | ECSP066549A (fr) |
GT (1) | GT200400226A (fr) |
HR (1) | HRP20060166A2 (fr) |
IL (1) | IL175283A0 (fr) |
IS (1) | IS8426A (fr) |
MA (1) | MA28151A1 (fr) |
MX (1) | MXPA06005023A (fr) |
NL (1) | NL1027434C2 (fr) |
NO (1) | NO20062618L (fr) |
OA (1) | OA13280A (fr) |
PA (1) | PA8616801A1 (fr) |
PE (1) | PE20050576A1 (fr) |
TN (1) | TNSN06129A1 (fr) |
TW (2) | TWI280245B (fr) |
WO (1) | WO2005044822A1 (fr) |
ZA (1) | ZA200603594B (fr) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10138275A1 (de) * | 2001-08-10 | 2003-02-27 | Boehringer Ingelheim Pharma | Verbindungen zur Beseitigung der Anhedonie |
EP1603585A2 (fr) * | 2003-03-14 | 2005-12-14 | Bristol-Myers Squibb Company | Polynucleotide codant un nouveau variant de recepteur de hm74, hgprbmy74 couple a une proteine g humaine |
US7151097B2 (en) * | 2003-11-07 | 2006-12-19 | Pfizer Inc. | Bicyclic pyrazolyl and imidazolyl compounds and uses thereof |
ITMI20041032A1 (it) * | 2004-05-24 | 2004-08-24 | Neuroscienze S C A R L | Compositi farmaceutici |
US20050288340A1 (en) * | 2004-06-29 | 2005-12-29 | Pfizer Inc | Substituted heteroaryl- and phenylsulfamoyl compounds |
US20060025448A1 (en) | 2004-07-22 | 2006-02-02 | Cadila Healthcare Limited | Hair growth stimulators |
JP2008514584A (ja) * | 2004-09-27 | 2008-05-08 | ファイザー・プロダクツ・インク | 二環式ピラゾリル化合物の製造方法 |
PA8660701A1 (es) | 2005-02-04 | 2006-09-22 | Pfizer Prod Inc | Agonistas de pyy y sus usos |
CA2605479A1 (fr) * | 2005-04-20 | 2006-10-26 | Pfizer Products Inc. | Composes acylaminobicycliques comportant un heteroatome et leurs utilisations |
JP2008542255A (ja) * | 2005-05-27 | 2008-11-27 | ファイザー・プロダクツ・インク | 肥満症の治療または体重減量の維持のためのカンナビノイド−1受容体アンタゴニストおよびミクロソームトリグリセリド輸送タンパク質阻害物質の併用 |
US8378117B2 (en) * | 2005-09-23 | 2013-02-19 | Janssen Pharmaceutica N.V. | Hexahydro-cycloheptapyrazole cannabinoid modulators |
US8378096B2 (en) * | 2005-09-23 | 2013-02-19 | Janssen Pharmaceutica N.V. | Hexahydro-cycloheptapyrazole cannabinoid modulators |
US7825151B2 (en) * | 2005-09-23 | 2010-11-02 | Janssen Pharmaceutica Nv | Hexahydro-cyclooctyl pyrazole cannabinoid modulators |
WO2007046550A1 (fr) * | 2005-10-21 | 2007-04-26 | Mitsubishi Tanabe Pharma Corporation | Composes pyrazole presentant une activite antagoniste du recepteur cannabinoide (cb1) |
WO2007060525A2 (fr) | 2005-11-28 | 2007-05-31 | Pfizer Products Inc. | Procédé de synthèse de composés bicycliques de type pyrazolyle et imidazolyle |
US8138188B2 (en) * | 2006-02-23 | 2012-03-20 | Pfizer Inc. | Melanocortin type 4 receptor agonist piperidinoylpyrrolidines |
EP2018863B9 (fr) | 2006-05-16 | 2015-02-18 | Takeda Pharmaceutical Company Limited | Composé hétérocyclique fusionné et utilisation |
WO2008048648A2 (fr) * | 2006-10-17 | 2008-04-24 | Acadia Pharmaceuticals Inc. | Composés modulant cb1 et utilisation de ces derniers |
EP2084127A1 (fr) | 2006-11-13 | 2009-08-05 | Pfizer Products Inc. | Dérivés diaryle, dipyridinyle et aryl-pyridinyle et leurs utilisations |
WO2009032754A2 (fr) * | 2007-08-31 | 2009-03-12 | Kalypsys, Inc. | Modulateurs des récepteurs cannabinoïdes à base d' hétérocyclodiazépine pour traiter une maladie |
EP2116618A1 (fr) | 2008-05-09 | 2009-11-11 | Agency for Science, Technology And Research | Diagnostic et traitement de la maladie de Kawasaki |
KR101280786B1 (ko) * | 2008-08-06 | 2013-07-05 | 화이자 리미티드 | 멜라노코르틴 4 작용제로서 다이아제핀 및 다이아조칸 화합물 |
US9549006B2 (en) * | 2013-07-31 | 2017-01-17 | Cisco Technology, Inc. | Self-adaptive sample period for content sharing in communication sessions |
SI3066085T1 (sl) * | 2013-11-08 | 2020-08-31 | Incyte Holdings Corporation | Postopek sinteze inhibitorja indolamina 2,3-dioksigenaze |
US11191814B2 (en) | 2018-09-04 | 2021-12-07 | Paw Power, Inc. | Pet food formulation with cannabinoids |
US11504416B2 (en) | 2018-09-04 | 2022-11-22 | Paw Power, Inc. | Formulation with cannabinoids |
MX2022000314A (es) | 2019-08-09 | 2022-02-10 | Nihon Nohyaku Co Ltd | Derivado de oxazepinona, insecticida agricola/horticola que contiene el mismo, y metodo para usar el mismo. |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004502642A (ja) | 2000-02-11 | 2004-01-29 | ブリストル−マイヤーズ スクイブ カンパニー | カンナビノイドレセプターモジュレーター、それらの製造方法、および呼吸系および非呼吸系疾患の処置のためのカンナビノイドレセプターモジュレーターの使用 |
EP1421077A4 (fr) | 2001-08-31 | 2004-11-17 | Univ Connecticut | Nouveaux analogues de pyrazole agissant sur les recepteurs cannabinoides |
EP1432708B1 (fr) | 2001-09-24 | 2005-11-30 | Bayer Pharmaceuticals Corporation | Preparation et utilisation de derives de la 1,5,6,7-tetrahydropyrrolo 3,2-c]pyridine pour le traitement de l'obesite |
GB0207249D0 (en) | 2002-03-27 | 2002-05-08 | Glaxo Group Ltd | Novel compounds |
BR0314872A (pt) * | 2002-10-18 | 2005-08-02 | Pfizer Prod Inc | Ligandos do receptor canabinóide e usos dos mesmos |
US7129239B2 (en) * | 2002-10-28 | 2006-10-31 | Pfizer Inc. | Purine compounds and uses thereof |
US7247628B2 (en) * | 2002-12-12 | 2007-07-24 | Pfizer, Inc. | Cannabinoid receptor ligands and uses thereof |
US7329658B2 (en) * | 2003-02-06 | 2008-02-12 | Pfizer Inc | Cannabinoid receptor ligands and uses thereof |
US7176210B2 (en) * | 2003-02-10 | 2007-02-13 | Pfizer Inc. | Cannabinoid receptor ligands and uses thereof |
US7141669B2 (en) * | 2003-04-23 | 2006-11-28 | Pfizer Inc. | Cannabiniod receptor ligands and uses thereof |
US20040214856A1 (en) | 2003-04-23 | 2004-10-28 | Pfizer Inc | Cannabinoid receptor ligands and uses thereof |
US7268133B2 (en) * | 2003-04-23 | 2007-09-11 | Pfizer, Inc. Patent Department | Cannabinoid receptor ligands and uses thereof |
US7145012B2 (en) * | 2003-04-23 | 2006-12-05 | Pfizer Inc. | Cannabinoid receptor ligands and uses thereof |
US7423031B2 (en) | 2003-05-01 | 2008-09-09 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
JP4041153B2 (ja) * | 2003-05-07 | 2008-01-30 | ファイザー・プロダクツ・インク | カンナビノイド受容体リガンドとその使用 |
US7232823B2 (en) | 2003-06-09 | 2007-06-19 | Pfizer, Inc. | Cannabinoid receptor ligands and uses thereof |
US20040259887A1 (en) | 2003-06-18 | 2004-12-23 | Pfizer Inc | Cannabinoid receptor ligands and uses thereof |
US20050026983A1 (en) | 2003-07-30 | 2005-02-03 | Pfizer Inc | Imidazole compounds and uses thereof |
US7151097B2 (en) * | 2003-11-07 | 2006-12-19 | Pfizer Inc. | Bicyclic pyrazolyl and imidazolyl compounds and uses thereof |
JP2008514584A (ja) * | 2004-09-27 | 2008-05-08 | ファイザー・プロダクツ・インク | 二環式ピラゾリル化合物の製造方法 |
-
2004
- 2004-10-22 US US10/971,599 patent/US7151097B2/en not_active Expired - Fee Related
- 2004-10-25 AU AU2004286909A patent/AU2004286909A1/en not_active Abandoned
- 2004-10-25 WO PCT/IB2004/003522 patent/WO2005044822A1/fr active Application Filing
- 2004-10-25 BR BRPI0416299-4A patent/BRPI0416299A/pt not_active IP Right Cessation
- 2004-10-25 EP EP04769741A patent/EP1682554A1/fr not_active Withdrawn
- 2004-10-25 CA CA002544752A patent/CA2544752A1/fr not_active Abandoned
- 2004-10-25 MX MXPA06005023A patent/MXPA06005023A/es not_active Application Discontinuation
- 2004-10-25 JP JP2006538974A patent/JP4056549B2/ja not_active Expired - Fee Related
- 2004-10-25 KR KR1020067008880A patent/KR20060086396A/ko active IP Right Grant
- 2004-10-25 AP AP2006003601A patent/AP2006003601A0/xx unknown
- 2004-10-25 CN CNA2004800352698A patent/CN1886407A/zh active Pending
- 2004-10-25 OA OA1200600145A patent/OA13280A/en unknown
- 2004-10-25 EA EA200600647A patent/EA009742B1/ru not_active IP Right Cessation
- 2004-11-02 PA PA20048616801A patent/PA8616801A1/es unknown
- 2004-11-02 TW TW093133372A patent/TWI280245B/zh not_active IP Right Cessation
- 2004-11-02 TW TW095142275A patent/TW200716135A/zh unknown
- 2004-11-03 DO DO2004001024A patent/DOP2004001024A/es unknown
- 2004-11-04 PE PE2004001074A patent/PE20050576A1/es not_active Application Discontinuation
- 2004-11-04 GT GT200400226A patent/GT200400226A/es unknown
- 2004-11-05 AR ARP040104075A patent/AR046831A1/es not_active Application Discontinuation
- 2004-11-05 NL NL1027434A patent/NL1027434C2/nl not_active IP Right Cessation
-
2006
- 2006-04-21 IS IS8426A patent/IS8426A/is unknown
- 2006-04-27 IL IL175283A patent/IL175283A0/en unknown
- 2006-05-04 HR HR20060166A patent/HRP20060166A2/xx not_active Application Discontinuation
- 2006-05-05 ZA ZA200603594A patent/ZA200603594B/en unknown
- 2006-05-05 CR CR8387A patent/CR8387A/es not_active Application Discontinuation
- 2006-05-05 TN TNP2006000129A patent/TNSN06129A1/fr unknown
- 2006-05-05 MA MA29005A patent/MA28151A1/fr unknown
- 2006-05-05 EC EC2006006549A patent/ECSP066549A/es unknown
- 2006-06-07 NO NO20062618A patent/NO20062618L/no not_active Application Discontinuation
- 2006-09-07 US US11/470,695 patent/US20070027133A1/en not_active Abandoned
-
2007
- 2007-07-12 JP JP2007183117A patent/JP2007302685A/ja not_active Withdrawn
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA28151A1 (fr) | Derives de pyrazolyle et d'imidazolyle bicycliques et leurs utilisations | |
TNSN05190A1 (fr) | DERIVES DE PYRAZOLO [1,5-a][1,3,5] TRIAZINE SERVANT DE LIGANDS DES RECEPTEURS DE CANNABINOIDES | |
TNSN05317A1 (fr) | Ligands des recepteurs de cannabinoides et leurs utilisations | |
EA200970326A1 (ru) | Алкильные производные в качестве метаботропных рецепторов глутамата | |
TNSN05121A1 (fr) | Purines et leurs utilisations comme ligands des recepteurs de cannabinoides | |
KR102684364B1 (ko) | 질환의 치료를 위한 kdm1a 저해제 | |
EA200501430A1 (ru) | Лиганды каннабиноидных рецепторов и их применение | |
MA27428A1 (fr) | Derives de pyrimidine et leur utilisation en tant que modulateurs cb2 | |
WO2007020502A3 (fr) | Ligands des recepteurs de cannabinoide et utilisations de ceux-ci | |
MA27448A1 (fr) | Derives de pyridine modulateurs du recepteur cb2 | |
MA29693B1 (fr) | Derives de xanthine en tant qu'agonistes hm74a selectifs | |
CL2004000861A1 (es) | Compuesto biciclico derivado de pirazol [4,3-d] pirimidin-7-ona o de pirazol [4,3-c] piridin-7-ona de formula definida, como ligando del receptor cannabinoide que actua como antagonista del receptor cb1; composicion farmaceutica que comprende al comp | |
ATE405558T1 (de) | Ketolactam-verbindungen und ihre verwendung | |
TNSN02012A1 (fr) | Derives de pyrimidine nouveaux inhibiteurs de mmp, et compositions les contenant | |
MA31158B1 (fr) | Composes tricycliques et leur utilisation comme modulateurs du recepteur de glucocorticoïdes | |
ATE411296T1 (de) | Imidazolinderivate mit cb1-antagonistischer wirkung | |
ATE496922T1 (de) | Mglur1-antagonisten als therapeutische wirkstoffe | |
ATE407119T1 (de) | Pyridinderivate und deren verwendung als modulatoren des cb2-rezeptors | |
EA200870074A1 (ru) | Производные 4,5-дигидро-(1н)-пиразола в качестве модуляторов каннабиноидного рецептора св1 | |
ATE340785T1 (de) | 2-phenylamino-4-trifluoromethyl-5-(benzyl- oder pyridin-4-ylmethyl)carbamoylpyrimidin-derivate als selektive cb2 cannabinoid-rezeptor modulatoren | |
MA27634A1 (fr) | Traitement de maladies proliferatives au moyen de derives d'epothilone et d'une exposition a des rayonnements | |
MA29694B1 (fr) | Derives de l'imidazopyridine comme ligands du recepteur cannabinoide | |
DE60224509D1 (de) | Imidazolderivate verwendbar als histamin h3 rezeptorliganden | |
ATE386519T1 (de) | Benzimidazole derivate und ihre anwendung als gaba a rezeptor komplex modulatoren | |
TNSN05082A1 (fr) | Derives de pyrazole servant d'inhibiteurs du facteur de croissance transformant (tgf) |